In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

First performed in 1963, lung transplantation is approaching the half-century mark. With
more than 32,000 procedures having been performed worldwide, lung transplantation has …

Background Antiviral-resistant or refractory cytomegalovirus (CMV) infection is challenging,
and salvage therapies, foscarnet, and cidofovir, have significant toxicities. Several …

We report the first case of cytomegalovirus (CMV) disease treated with AIC246, a novel anti-
CMV compound which targets the viral terminase complex and remains active against virus …

Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a
novel antiviral recently approved for CMV prophylaxis following hematopoietic cell …

Mutations in the human CMV UL97 kinase gene are a major mechanism of viral resistance
to two anti‐CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used …

Opinion statement In treating cytomegalovirus (CMV) infection, it is crucial to decide whether
one is treating pre-emptively or if one is treating established disease. Disease may be …

Human cytomegalovirus (HCMV) is a pathogen that can be life-threatening in
immunocompromised individuals. Valganciclovir and its parent drug ganciclovir are …

ABSTRACT A strain of human cytomegalovirus, T2211, modified from standard laboratory
strain AD169 to contain a secreted alkaline phosphatase reporter gene for rapid viral …

Ganciclovir-resistant cytomegalovirus (CMV) infections are reported infrequently among
lung transplant recipients receiving extended valganciclovir prophylaxis. We performed a …